Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
761.700.12%
QQQ
715.400.21%
BTC/USD
76336.580.1691%
DIA
517.830.1%
GLD
398.270.02%
TLT
81.720.07%

Denali Therapeutics Inc (DNLI) Stock Price, Quote, News & History

DNLINASDAQ
Trade with Public
Trade with Public
$20.13
0.070.35%
At close: Sep 17, 5:00 PM EST
$20.13
N/A
After Hours: 4:19 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Denali Therapeutics (DNLI) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$20.57
Close
$20.13
Volume / Avg.
1.42M / 1.59M
Day Range
$19.90 - $20.65
52 Wk Range
12.58 - 27.30
Market Cap
$3.22B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
25
Short Interest
10.98%
Days to Cover
17.5

Recent Denali Therapeutics Inc. News

Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out'

Nancy Pelosi Stock Tracker highlighted Claude AI's Denali Therapeutics earnings bet, which targets upside from its rare-disease drug launch.
Ananya Gairola

Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
Avi Kapoor

Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why

Denali shares fall after Takeda exits DNL593 deal; company regains full rights and targets Phase 1/2 data readout by late 2026.
Vandana Singh

Arm Holdings To Rally Over 27%? Here Are 10 Top Analyst Forecasts For Thursday

Wall Street analysts change ratings on top stocks: BNP Paribas cuts Chewy Inc, Bernstein cuts Qualcomm, Wells Fargo raises United Natural Foods.
Avi Kapoor

FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease

Denali Therapeutic snags FDA accelerated approval for Avlayah for Hunter syndrome, analyst flags strong launch potential.
Vandana Singh

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-434.04M
Investing Cash Flow (TTM)
68.98M
Financing Cash Flow (TTM)
425.38M
Free Cash Flow (TTM)
-466.26M
Capital Expenditure (TTM)
-32.22M
Net Change in Cash (TTM)
60.32M

Analyst Trends and Forecast

6
Mar
2
Apr
4
May
3
Jul
2
Aug
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$2.53B
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
1004.00
PB Ratio (TTM)
3.84
Earnings Yield % (TTM)
-14.16%
Earnings Yield % (FWD)
-13.04%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$5.22

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-$1.42M
Total Cash
$201.53M
Debt to Equity
0.04
Issuance of Debt (TTM)
-$1.42M
Repayment of Debt (TTM)
-$1.42M

Key Statistics

Open
$20.57
Close
$20.13
Volume / Avg.
1.42M / 1.59M
Day Range
$19.90 - $20.65
52 Wk Range
12.58 - 27.30
Market Cap
$3.22B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
25
Short Interest
10.98%
Days to Cover
17.5

About

Sector
Health Care
Industry
Biotechnology
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Denali Therapeutics (DNLI) stock?

A

You can purchase shares of Denali Therapeutics (NASDAQ:DNLI) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Denali Therapeutics (DNLI) competitors?

Q

What is the forecast, or price target, for Denali Therapeutics (DNLI) stock?

A

Denali Therapeutics has a consensus price target of $35.16.

Q

What is the current price for Denali Therapeutics (DNLI)?

A

The stock price for Denali Therapeutics (NASDAQ: DNLI) is $20.13 last updated September 17, 2026 at 4:19 PM EDT.

Q

Does Denali Therapeutics (DNLI) pay a dividend?

A

There are no upcoming dividends for Denali Therapeutics.

Q

When is Denali Therapeutics (NASDAQ:DNLI) reporting earnings?

A

Denali Therapeutics does not have any upcoming earnings scheduled.

Q

Is Denali Therapeutics (DNLI) going to split?

A

There is no upcoming split for Denali Therapeutics.

Q

What sector and industry does Denali Therapeutics (DNLI) operate in?

A

Denali Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved